Skip to main content
. 2022 Jan 21;12:1134. doi: 10.1038/s41598-022-05138-6

Table 1.

Characteristics of 103 patients with AE-IPF.

Overall (n = 103) Survivors (n = 55) Non-survivors (n = 48) P value
Male sex n (%) 88 (85.4%) 45(81.8%) 43(89.6%) 0.4
Age median (range) 73.7 ± 6.9 73.4 ± 7.2 74.1 ± 6.6 0.76
Smoking history
Never/former/current 19/81/3 10/44/1 9/37/2 0.98
Pack-years (mean ± SD) 57.9 ± 31.2 58.3 ± 29.3 56.4 ± 34.3 0.56
%FVC 71.0 ± 71.8 72.9 ± 21.0 68.6 ± 19.1 0.44
%DLco 35.5 ± 30.4 37.2 ± 29.6 33.6 ± 31.4 0.57
GAP score 2.7 ± 2.2 2.8 ± 2.3 2.6 ± 2.2 0.68
Laboratory and radiological findings at the onset of AE-IPF
PaO2/FiO2 ratio 252.2 ± 85.6 283.3 ± 79.3 217.4 ± 79.3 < 0.001*
KL-6 (U/ml) 1535.3 ± 1856.8 1291.4 ± 875.2 1748.2 ± 2397.2 0.58
SP-D (ng/ml) 438.6 ± 356.6 395.9 ± 321.9 487.6 ± 390.3 0.22
SP-A (ng/ml) 103.0 ± 58.5 101.9 ± 60.6 104.4 ± 56.5 0.98
LDH (U/l) 373.9 ± 186.1 329.1 ± 68.7 424.3 ± 253.3 0.007*
CRP (mg/dl) 8.0 ± 6.4 6.2 ± 5.5 10.0 ± 6.9 0.002*
Diffuse HRCT pattern, n (%) 73 (70.9) 30 (54.5) 43 (89.6) < 0.001*

%FVC, Forced vital capacity, % of predicted value; %DLco, Carbon monoxide diffusing capacity -% of predicted value; GAP score. Gender-Age-Physiology score; KL-6, Krebs von der Lungen-6; SP-D, surfactant protein D; SP-A, surfactant protein A; LDH, lactate dehydrogenase; CRP, C-reactive protein; HRCT, high-resolution computed tomography; CS, corticosteroid, PMX-DHP, Polymyxin B-immobilized fiber column-direct hemoperfusion; rhTM, recombinant human thrombomodulin.

*P < 0.05.